HIGHLIGHTS
- who: Xenofon Baraliakos from the Institutional review board JAK have published the Article: Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies, in the Journal: (JOURNAL)
- what: The aim of this post-hoc analysis was to assess the efficacy and safety of upadacitinib in psoriatic arthritis (PsA) patients with axial involvement. This analysis shows that PsA patients with axial involvement treated with upadacitinib 15 mg using either of the predefined criteria showed improvements in measures of axial disease, including ASDAS and modified BASDAI (excluding . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.